gemcitabine has been researched along with Kahler Disease in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Gowda, PS; Javed, A; Li, J; Lu, Y; Ponnazhagan, S; Trotter, TN; Xu, X; Yang, Y; Zhang, C | 1 |
| Andersson, BS; Bashir, Q; Li, Y; Liu, Y; Murray, D; Nieto, Y; Qazilbash, MH; Valdez, BC | 1 |
| Bacher, U; Betticher, D; Farag, S; Farese, S; Jeker, B; Li, Q; Luethi, JM; Mueller, BU; Novak, U; Pabst, T; Ruefer, A; Taleghani, BM | 1 |
| Gahrton, G | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Murray, D; Nieto, Y; Qazilbash, MH; Shah, J; Turturro, F; Valdez, BC; Wang, G; Wang, M; Weber, DM | 1 |
| Carafa, M; Celia, C; Cilurzo, F; Di Marzio, L; Gentile, E; Paolino, D; Ventura, CA; Wolfram, J | 1 |
| Yang, F; Zheng, H | 1 |
| Betticher, D; Egger, T; Keller, S; Mansouri Taleghani, B; Mueller, BU; Pabst, T; Rauch, D; Seipel, K | 1 |
| Bagnobianchi, A; Bingham, JP; Craddock, C; Hartley, JA; Hochhauser, D; Kiakos, K; Ledermann, JA; Lowe, HL; Newton, C; Spanswick, VJ | 1 |
| Alesiani, F; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Offidani, M; Olivieri, A; Rupoli, S | 1 |
| Dumontet, C | 1 |
| Gajria, D; Gandhi, V; Ghias, K; Krett, NL; Nabhan, C; Rosen, ST | 1 |
| Ayres, M; Gandhi, V; Krett, NL; Ma, C; Nabhan, C; Nawrocki, S; Nowak, B; Rosen, ST | 1 |
| Bouafia, F; Dumontet, C; Facon, T; Leleu, X; Michallet, M; Troncy, J | 1 |
| Alsina, M; Beam, C; Beaupre, DM; Dalton, W; Gerbino, E; Hamilton, AD; Kerr, WG; Lichtenheld, MG; Mackley, PA; Muro-Cacho, C; Sebti, SM; Zhu, K | 1 |
| Cottler-Fox, M; Fassas, A; Fenton, R; French, T; Gojo, I; Guo, C; Heyman, M; Meisenberg, B; Murthy, A; Philips, GL; Rapoport, AP; Ruehle, K; Sarkodee-Adoo, C; Takebe, N; Tan, M; Tricot, G | 1 |
| Gazitt, Y; Rothenberg, ML; Shaughnessy, P | 1 |
| Bruchertseifer, F; Chatal, JF; Chérel, M; Davodeau, F; Gouard, S; Mahé, MA; Morgenstern, A; Rio, E; Supiot, S; Thillays, F | 1 |
| Celia, C; Cosco, D; Fresta, M; Malara, N; Paolino, D; Savino, R; Terracciano, R | 1 |
| Boeck, G; Egle, A; Geisen, F; Greil, R; Gruber, J; Konwalinka, G; Sgonc, R; Villunger, A | 1 |
| Fey, V; Gazitt, Y; Hilsenbeck, SG; Montegomrey, W; Rothenberg, ML; Thomas, C | 1 |
| Barlogie, B; Crowley, JJ; Hussein, MA; Moore, DF; Weick, JK | 1 |
3 review(s) available for gemcitabine and Kahler Disease
| Article | Year |
|---|---|
Liposomal chemotherapeutics.
Topics: Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Female; Gemcitabine; Humans; Liposomes; Multiple Myeloma; Paclitaxel; Pancreatic Neoplasms; Thyroid Neoplasms | 2013 |
Gemcitabine in treating patients with refractory or relapsed multiple myeloma.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Multiple Myeloma; Recurrence; Salvage Therapy | 2014 |
[The role of gemcitabine in hematology].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Design; Gemcitabine; Hematologic Neoplasms; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Multiple Myeloma; Neoplasm Proteins; Nucleotides; Ribonucleotide Reductases; Salvage Therapy; Treatment Outcome | 2002 |
5 trial(s) available for gemcitabine and Kahler Disease
| Article | Year |
|---|---|
A randomized evaluation of vinorelbine versus gemcitabine chemotherapy mobilization of stem cells in myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Mobilization; Humans; Multiple Myeloma; Stem Cells; Vinorelbine | 2020 |
Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Life Tables; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome | 2002 |
Evaluation of gemcitabine in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Multiple Myeloma | 2004 |
A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Multiple Myeloma; Paclitaxel; Recurrence; Time Factors; Treatment Outcome | 2006 |
The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local | 2002 |
14 other study(ies) available for gemcitabine and Kahler Disease
| Article | Year |
|---|---|
Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Topics: Animals; Bone and Bones; Bone Marrow; Bone Neoplasms; Cell Line, Tumor; Core Binding Factor Alpha 1 Subunit; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Knockout; Multiple Myeloma; Myeloid-Derived Suppressor Cells; Osteoblasts; Tumor Microenvironment | 2020 |
Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Cell Line, Tumor; Cytotoxins; Deoxycytidine; DNA Fragmentation; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Humans; Melphalan; Membrane Potential, Mitochondrial; Multiple Myeloma; Neoplasm Proteins; Panobinostat; Signal Transduction; Sulfonamides | 2020 |
Gemcitabine, busulfan, and melphalan conditioning for autologous stem-cell transplants in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Transplantation Conditioning; Transplantation, Autologous | 2017 |
Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Base Sequence; Cell Line, Tumor; Clofarabine; Deoxycytidine; DNA Damage; DNA Primers; DNA Repair; Drug Synergism; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Suppressor Protein p53 | 2013 |
Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Polyneuropathies; Transplantation, Autologous; Treatment Outcome | 2016 |
Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA; DNA Damage; DNA Repair; DNA Replication; Drug Resistance, Neoplasm; Female; Gemcitabine; Histones; Homologous Recombination; Humans; Melphalan; Multiple Myeloma; Ovarian Neoplasms; Rad51 Recombinase; Signal Transduction | 2012 |
Caspase activation is required for gemcitabine activity in multiple myeloma cell lines.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Cycle; Cell Division; Deoxycytidine; Drug Combinations; Enzyme Activation; Flow Cytometry; Gemcitabine; Humans; Immunoblotting; Interleukin-6; Membrane Potentials; Mitochondria; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Tumor Cells, Cultured | 2002 |
In vitro assessment of nucleoside analogs in multiple myeloma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Multiple Myeloma; Nucleosides; Tumor Cells, Cultured | 2004 |
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow Cells; Caspase 3; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials as Topic; Cytochromes c; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Enzyme Activation; Farnesyltranstransferase; Flow Cytometry; Fluorouracil; G2 Phase; Gemcitabine; Homozygote; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Mice; Mice, SCID; Mitosis; Multiple Myeloma; Paclitaxel; Quinolones; Taxoids; Tetrazolium Salts; Thiazoles | 2005 |
Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Gemcitabine radiosensitizes multiple myeloma cells to low let, but not high let, irradiation.
Topics: Alpha Particles; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Gamma Rays; Gemcitabine; Humans; Linear Energy Transfer; Multiple Myeloma; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents | 2007 |
Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Gemcitabine; Humans; Liposomes; Multiple Myeloma | 2008 |
2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).
Topics: 2-Chloroadenosine; Antimetabolites, Antineoplastic; Apoptosis; Biotin; Deoxyadenosines; Deoxycytidine; Deoxyuracil Nucleotides; Dexamethasone; DNA Damage; Drug Resistance; Gemcitabine; Glucocorticoids; Hematopoietic Stem Cells; Humans; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sensitivity and Specificity; Staining and Labeling; Steroids; Tumor Cells, Cultured | 1996 |
Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Deoxycytidine; Drug Resistance; Gemcitabine; Humans; Multiple Myeloma; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |